What if the test that could have caught your cancer earlier never existed — not because the science wasn’t there, but because a political dispute shut the lab down?

That is exactly what a recent KFF Health News investigation reveals. Researcher Joan Brugge spent six years at Harvard Medical School identifying the earliest cellular seeds of breast cancer. This painstaking work could one day make the disease preventable. Then the Trump administration froze her $7 million NIH grant over a dispute with Harvard. Seven of her 18 staff members left. Months of irreplaceable research time vanished. Her grant now ends this August — and the next phase of her research may never happen.

The consequences don’t stop in Boston. They flow directly to Washington state. Fred Hutchinson Cancer Center and UW Medicine form a research and clinical ecosystem that attracts federal funding and trains many of the state’s oncologists. Meanwhile, Harborview Medical Center is the only Level I trauma center serving Washington, Alaska, Montana, and Idaho. It depends on that same ecosystem to serve the state’s most vulnerable patients. The Trump administration is proposing to cut the NIH budget by nearly 40%. These institutions absorb the blow first. Washington patients feel it next.

And that matters enormously. The gap between the care patients receive and the care they should have received is the foundation of a medical malpractice claim. A missed breast cancer diagnosis, a failure to order appropriate screening, and treatment that lags behind established best practices can all constitute medical negligence under Washington law. When the research that defines those standards disappears, the legal protections built around them weaken too. Washington patients deserve a system that protects them before harm occurs, not after.